Anas Younes: Decade-Long Persistence of CD19 CAR T Cells in B Cell Lymphomas
oncodaily - Anas Younes, Chief Medical Officer and Head of Haematology R&D at AstraZeneca, shared on LinkedIn: “While these findings demonstrate that CART19 cells can persist for more than 10 years in […]
AI Summary: Long-term follow-up shows CD19-directed CAR‑T cells can persist for a decade in patients with B‑cell lymphomas, associating with sustained remissions and reshaping expectations about durability, retreatment and long-term toxicity. These findings prompt rethinking of follow-up care and suggest cellular therapies may offer far longer benefits than anyone dared hope.
Related Stories
Ten‑year follow‑up shows durable remissions with CD19 CAR‑T therapy / 2 months
ENZAMET trial confirms long-term survival benefit of enzalutamide in mHSPC / 8 days
Nine‑year CheckMate‑214 follow‑up confirms durable immunotherapy benefit / 1 month
Teclistamab shows survival benefit prompting earlier use discussions / 2 months
CAR-PRISM trial shows BCMA CAR T effective in high-risk smoldering myeloma / 4 months
Long‑term immunotherapy appears safe for alveolar soft part sarcoma / 4 months
Zongertinib emerges as first-line therapy for HER2‑mutant NSCLC / 4 months
StackHealth RSS
You can now follow topics by RSS - browse the complete list of topics, people, and organizations. Or, try Zoonotic Disease, Product Recall, CDC, Health IT and look for the RSS link.
StackHealth Time Machine